HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
ceronapril
structure given in first source; RN given for (S)-isomer
Also Known As:
1-(6-amino-2-((hydroxy(4-phenylbutyl)phosphinyl)oxy)-1-oxohexyl)proline; SQ 29852; SQ-29,852; ceranapril
Networked:
6
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Organophosphorus Compounds: 300
ceronapril: 6
Amino Acids, Peptides, and Proteins: 1
Amino Acids: 30675
Cyclic Amino Acids: 3
Imino Acids: 11
Proline: 3391
ceronapril: 6
Related Diseases
1.
Alzheimer Disease (Alzheimer's Disease)
08/06/1991 - "
The present study assesses the binding density of the selective angiotensin converting enzyme (ACE) radioligand [3H]ceranapril in brain tissue homogenates derived from patients with Alzheimer's disease and those from age-, sex- and post-mortem delay-matched neurologically normal patients.
"
01/01/1993 - "
A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease.
"
2.
Hypertension (High Blood Pressure)
06/01/1996 - "
To assess the effect of the angiotensin-converting enzyme inhibitor ceronapril on cerebral blood flow (CBF) in patients with moderate hypertension.
"
07/01/1994 - "
Intracerebroventricular administration of ceronapril, an angiotensin converting enzyme inhibitor, significantly decreased sustained high blood pressure in SHR 48 h after nephrectomy compared with vehicle administration, whereas intravenous administration had no effect.
"
3.
Tachycardia (Tachyarrhythmias)
07/01/1994 - "
1. To test the hypothesis that a central mechanism may play a role in the minimal reflex tachycardia noted in response to peripheral converting enzyme inhibition, we compared the effects of intravenous (i.v.) ceronapril (CER) with nitroglycerin (NTG) on neurotransmitter release in the rostral ventrolateral medulla (RVLM), using an in vivo microdialysis method in pentobarbital anaesthetized rats.
"
4.
Shock
07/01/1992 - "
We assessed this possibility by determining the effects of ceronapril on latent inhibition using a conditioned emotional response procedure, consisting of three stages: pre-exposure, in which the to-be-conditioned stimulus, a tone, was repeatedly presented without reinforcement; conditioning, in which the pre-exposed stimulus was paired with shock; and test, where latent inhibition was indexed by animals' suppression of licking during tone presentation.
"
07/01/1992 - "
In Experiment 2, five tone pre-exposures were given, and conditioning consisted of two tone-shock pairings: we assessed the effects of 0.05 mg/kg ceronapril, compared with vehicle injections.(ABSTRACT TRUNCATED AT 250 WORDS)
"
07/01/1992 - "
In Experiment 1, 20 tone pre-exposures were given, and conditioning consisted of five tone-shock pairings; we assessed the effects of 0.005 mg/kg, 0.05 mg/kg and 0.5 mg/kg ceronapril, compared with vehicle injections.
"
5.
Dementia (Dementias)
01/01/1993 - "
This pilot clinical trial was a 15-week, double-blind, controlled, three-way crossover study evaluating cognitive effects of ceranapril in subjects with dementia of the Alzheimer type (age range 50-75 years).
"
Related Drugs and Biologics
1.
Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
2.
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.
Neurotransmitter Agents (Neurotransmitter)
4.
Pentobarbital (Nembutal)
5.
Nitroglycerin (Dynamite)
6.
Enzymes
Related Therapies and Procedures
1.
Intravenous Administration
2.
Nephrectomy
3.
Injections